TC-3 gel

DEVICE2 trials

Sponsors

UroGen Pharma Ltd.

Conditions

Carcinoma of Urinary Bladder, InvasiveOveractive Bladder

Phase 1

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence (INTIMO2)

WithdrawnNCT02674269

UroGen Pharma Ltd.Overactive Bladder

Start: 2016-10-31End: 2016-10-31Updated: 2017-06-16

Unknown Phase

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

CompletedNCT01648010

UroGen Pharma Ltd.Carcinoma of Urinary Bladder, Invasive

Start: 2011-11-30End: 2013-05-31Updated: 2013-05-07